These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24940647)

  • 41. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fingolimod treatment for multiple sclerosis patients What do we do with varicella?
    Winkelmann A; Loebermann M; Reisinger EC; Hartung HP; Zettl UK
    Ann Neurol; 2011 Oct; 70(4):673-4; author reply 674. PubMed ID: 22028236
    [No Abstract]   [Full Text] [Related]  

  • 43. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?
    Ferraro D; Federzoni L; Vitetta F; Simone A; Cossarizza A; Nichelli P; Sola P
    Mult Scler; 2013 Oct; 19(11):1550. PubMed ID: 23695445
    [No Abstract]   [Full Text] [Related]  

  • 47. [New disease-modifying and symptomatic therapies for multiple sclerosis].
    Weise G; Buttmann M
    MMW Fortschr Med; 2012 Apr; 154(7):64-6. PubMed ID: 22558878
    [No Abstract]   [Full Text] [Related]  

  • 48. Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
    Wise J
    BMJ; 2012 Feb; 344():e1360. PubMed ID: 22362460
    [No Abstract]   [Full Text] [Related]  

  • 49. Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating?
    Mori M
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):823. PubMed ID: 25855398
    [No Abstract]   [Full Text] [Related]  

  • 50. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppressive therapy and post-transplant malignancy.
    Domhan S; Zeier M; Abdollahi A
    Nephrol Dial Transplant; 2009 Apr; 24(4):1097-103. PubMed ID: 18978068
    [No Abstract]   [Full Text] [Related]  

  • 53. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
    Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM
    N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
    Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fingolimod.
    Prescrire Int; 2011; 20(118):173-4, 176-7. PubMed ID: 21751747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple sclerosis: Study reinforces need for contraception in women taking fingolimod.
    Jones B
    Nat Rev Neurol; 2014 Mar; 10(3):125. PubMed ID: 24514867
    [No Abstract]   [Full Text] [Related]  

  • 58. [Multiple sclerosis and pregnancy].
    Ruuskanen J; Malm H; Airas L
    Duodecim; 2013; 129(14):1457-64. PubMed ID: 23961604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New drugs 2011 part 2.
    Hussar DA
    Nursing; 2011 Jun; 41(6):36-41; quiz 41-2. PubMed ID: 21552174
    [No Abstract]   [Full Text] [Related]  

  • 60. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.